Latham & Watkins advised CVC Capital Partners ("CVC") on CVC Fund VI's acquisition of Teva Pharmaceutical Industries Ltd’s international women's health assets. The transaction was agreed in Q3 2017 and closed on 1 February 2018.

The new company, called Theramex, is a global specialty pharmaceutical company dedicated to women and their health. Headquartered in London, UK, the company will market a broad range of innovative, branded and branded generic products across 50 countries around the world. The portfolio, which is dedicated to women's health, focuses on contraception, fertility, menopause and osteoporosis.

Latham & Watkins represented CVC in the transaction with a London team led by corporate partner Robbie McLaren with associates Karima Salway, Emily Cridland, Samantha Peacock, Ei Nge Htut and Andria Varnavides. Advice was also provided on IP matters by partner Gail Crawford with associate Rachael Hammond, on supply and regulatory matters by Frances Stocks Allen and Terese Saplys, and on employment matters by associate Shaun Thompson.